At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02197 CLOVER BIO-B
Trading 08-05 11:20:55
2.195
+0.065
+3.05%
High2.280Low2.055Vol2.44M
Open2.065D1 Closing2.130Amplitude10.56%
Mkt Cap2.85BTradable Cap2.85BTotal Shares1.30B
T/O5.40MT/O Rate0.19%Tradable Shares1.30B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
With Clover Biopharmaceuticals Up 10%, Insider Buyers Count Their Returns
Simply Wall St.  ·  07-25
With Clover Biopharmaceuticals Up 10%, Insider Buyers Count Their Returns
Cellectar Biosciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Radiotherapy Pipeline, Led by Iopofosine I-131 in Waldenstrom Macroglobulinemia
Reuters  ·  07-21
Cellectar Biosciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Radiotherapy Pipeline, Led by Iopofosine I-131 in Waldenstrom Macroglobulinemia
CLOVER BIO-B Anticipates Mid-Year Profit Turnaround with Projected Net Income of 9.57 to 12.04 Billion Yuan
Stock News  ·  07-20
CLOVER BIO-B Anticipates Mid-Year Profit Turnaround with Projected Net Income of 9.57 to 12.04 Billion Yuan
Clover Biopharmaceuticals - Expects Net Profit of Rmb957 Mln–rmb1204 Mln for Six Months Ended June 30, 2026
THOMSON REUTERS  ·  07-20
Clover Biopharmaceuticals - Expects Net Profit of Rmb957 Mln–rmb1204 Mln for Six Months Ended June 30, 2026
Clover Biopharma Reports No Share Changes in June; 1.30 Billion Shares Remain Outstanding
Bulletin Express  ·  07-03
Clover Biopharma Reports No Share Changes in June; 1.30 Billion Shares Remain Outstanding
CLOVER BIO-B Adopts Sixth Amended & Restated Memorandum and Articles of Association; Authorised Share Capital Fixed at US$0.20 Million
Bulletin Express  ·  06-18
CLOVER BIO-B Adopts Sixth Amended & Restated Memorandum and Articles of Association; Authorised Share Capital Fixed at US$0.20 Million
Clover Biopharma shareholders adopt financial statements, re-elect directors at AGM
Reuters  ·  06-18
Clover Biopharma shareholders adopt financial statements, re-elect directors at AGM
Clover Bio-B Strengthens Internal Controls on Share Trading After Model Code Lapses
Bulletin Express  ·  06-05
Clover Bio-B Strengthens Internal Controls on Share Trading After Model Code Lapses
Clover Biopharma tightens share-trading controls for grantors after Model Code breaches
Reuters  ·  06-05
Clover Biopharma tightens share-trading controls for grantors after Model Code breaches
Clover Biopharmaceuticals Issues 0.18 Million New Shares in May on Option Exercises
Bulletin Express  ·  06-03
Clover Biopharmaceuticals Issues 0.18 Million New Shares in May on Option Exercises
Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia
Reuters  ·  06-02
Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia
Cellectar says iopofosine I-131 posts 79.2% major response rate in Phase 2 CLOVER-WaM subgroup after BTK inhibitors
Reuters  ·  06-01
Cellectar says iopofosine I-131 posts 79.2% major response rate in Phase 2 CLOVER-WaM subgroup after BTK inhibitors
Clover Biopharm sets 18 June 2026 AGM; targets 10% buy-back, 20% new-issue headroom and constitutional overhaul
Bulletin Express  ·  05-26
Clover Biopharm sets 18 June 2026 AGM; targets 10% buy-back, 20% new-issue headroom and constitutional overhaul
Clover Biopharmaceuticals Adds 0.02% to Share Base after Option Exercises in April
Bulletin Express  ·  05-06
Clover Biopharmaceuticals Adds 0.02% to Share Base after Option Exercises in April
三叶草生物医药：2025年经营亏损显著收窄，呼吸道疫苗管线持续推进
Bulletin Express  ·  04-23
三叶草生物医药：2025年经营亏损显著收窄，呼吸道疫苗管线持续推进
Clover Biopharma Reminds Non-Registered Shareholders of Shift to Electronic Dissemination of Corporate Communications
Bulletin Express  ·  04-23
Clover Biopharma Reminds Non-Registered Shareholders of Shift to Electronic Dissemination of Corporate Communications
Clover Biopharmaceuticals Implements Full Electronic Dissemination of Corporate Communications, Seeks Shareholders’ Email Details
Bulletin Express  ·  04-23
Clover Biopharmaceuticals Implements Full Electronic Dissemination of Corporate Communications, Seeks Shareholders’ Email Details
Cellectar CLOVER-WaM trial data accepted for ASCO 2026 poster presentation
Reuters  ·  04-21
Cellectar CLOVER-WaM trial data accepted for ASCO 2026 poster presentation
Clover BioPharma Adds 1,000 Shares via Option Exercise; Outstanding Post-IPO Options Rise to 42.85 Million
Bulletin Express  ·  04-09
Clover BioPharma Adds 1,000 Shares via Option Exercise; Outstanding Post-IPO Options Rise to 42.85 Million
CLOVER BIO-B Shares Surge Over 7% Again on Progress in Respiratory Combo Vaccine Trial
Stock News  ·  04-09
CLOVER BIO-B Shares Surge Over 7% Again on Progress in Respiratory Combo Vaccine Trial

Introduction

Company Name.
CLOVER BIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Clover Biopharmaceuticals Ltd is an investment holding company primarily engaged in the research and development, manufacture and commercialization of innovative vaccines. The Company’s products and candidates include Respiratory Syncytial Virus (RSV) Vaccine (SCB-1019), seasonal quadrivalent influenza vaccine AdimFlu-S, SCB-219M, COVID-19 Vaccine and others. The Company leverages the Trimer-Tag technology platform to conduct research and development (R&D) for innovative vaccines that can fulfill unmet need, with a focus on building a respiratory vaccine franchise and establishing a presence in the pediatric vaccine market. The Trimer-Tag is a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets. The Company conducts its business in the domestic and overseas markets.
Issue price:
--